[Form 4] Lifecore Biomedical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Key take-away: Leidos Holdings, Inc. (LDOS) has filed a Form 4 indicating routine director compensation in stock.

On 10 July 2025, the company reported that director Harry M. Jansen Kraemer Jr. acquired 200.5059 shares of Leidos common stock on 8 July 2025. The shares were credited at a price of $0.00 because the director elected to defer his quarterly board retainer into the company’s Key Executive Stock Deferral Plan. After the transaction, Mr. Kraemer’s indirect holdings in the plan total 127,890.1673 shares. No open-market purchases, dispositions, or derivative security activities were reported.

The filing reflects standard board compensation practice and does not materially affect Leidos’ share count or insider ownership profile.

Insights

Financial Analyst

TL;DR: Small, routine director stock accrual; negligible financial impact.

This Form 4 shows a non-cash, compensation-related issuance of ~200 shares to a board member. The resulting 127.9 k indirect shares remain immaterial in the context of Leidos’ ~137 m outstanding shares. No trading signal or governance concern arises; it is simply the continued use of the company’s deferred-compensation vehicle. Accordingly, the disclosure is operationally and financially neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salus Thomas D.

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MN 55318

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Administration

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2025		M		37,000(1)	A	(2)	252,000	D
Common Stock	07/08/2025		F		11,022(3)	D	$8.19	240,978	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Restricted Stock Units	(2)	07/08/2025		M			37,000	(2)	04/14/2030	Common Stock	37,000	(2)	333,000	D

Explanation of Responses:

1. The performance-based restricted stock units vested based on the Issuer's achievement of a stock price milestone.

2. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon the Issuer's common stock achieving certain stock prices.

3. Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the performance stock unit award as reported in Table I.

Remarks:

	/s/ Aaron S. Perlitsh, Attorney-In-Fact for Thomas D Salus	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Leidos (LDOS) disclose in the latest Form 4 filing?

A director acquired 200.5059 common shares on 08-Jul-2025 through the Key Executive Stock Deferral Plan.

How many LDOS shares does Harry M. Jansen Kraemer Jr. now own indirectly?

He holds 127,890.1673 shares indirectly after the reported transaction.

What was the purchase price of the shares acquired?

The shares were credited at $0.00 because they represent deferred board retainer compensation.

Did the filing report any derivative security transactions?

No. Table II shows no derivative securities acquired or disposed of.

Is the transaction linked to a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the acquisition was made under a 10b5-1 plan.